Adjuvant Capital — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
Co-investorsBioRock VenturesFlucas VenturesMountain Group CapitalRA CapitalBiotechnology Value FundHatteras Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.